Rational Advisors LLC Sells 23,500 Shares of Boston Scientific Co. (NYSE:BSX)

Rational Advisors LLC trimmed its position in Boston Scientific Co. (NYSE:BSX) by 62.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,200 shares of the medical equipment provider’s stock after selling 23,500 shares during the quarter. Rational Advisors LLC’s holdings in Boston Scientific were worth $1,190,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of BSX. Impax Asset Management Group plc boosted its position in shares of Boston Scientific by 17.5% during the 3rd quarter. Impax Asset Management Group plc now owns 5,470,174 shares of the medical equipment provider’s stock valued at $457,138,000 after purchasing an additional 815,403 shares in the last quarter. Quintet Private Bank Europe S.A. increased its stake in shares of Boston Scientific by 26.3% in the third quarter. Quintet Private Bank Europe S.A. now owns 23,581 shares of the medical equipment provider’s stock worth $1,976,000 after purchasing an additional 4,914 shares in the last quarter. World Equity Group Inc. bought a new position in shares of Boston Scientific in the third quarter valued at approximately $270,000. PDS Planning Inc boosted its position in shares of Boston Scientific by 2.7% during the 3rd quarter. PDS Planning Inc now owns 7,361 shares of the medical equipment provider’s stock valued at $617,000 after acquiring an additional 192 shares during the last quarter. Finally, TKG Advisors LLC bought a new stake in Boston Scientific during the third quarter worth about $2,180,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Performance

NYSE BSX opened at $84.72 on Tuesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61. The stock has a 50-day simple moving average of $84.10 and a two-hundred day simple moving average of $78.55. The firm has a market capitalization of $124.76 billion, a P/E ratio of 70.02, a PEG ratio of 2.47 and a beta of 0.79. Boston Scientific Co. has a fifty-two week low of $50.84 and a fifty-two week high of $88.79.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.41%. The business had revenue of $4.21 billion during the quarter, compared to analysts’ expectations of $4.04 billion. During the same quarter in the prior year, the company posted $0.50 EPS. The business’s revenue for the quarter was up 19.3% on a year-over-year basis. On average, equities analysts forecast that Boston Scientific Co. will post 2.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on BSX. Raymond James increased their price target on shares of Boston Scientific from $91.00 to $94.00 and gave the company a “strong-buy” rating in a research report on Wednesday, September 4th. Citigroup increased their price objective on shares of Boston Scientific from $92.00 to $98.00 and gave the company a “buy” rating in a research report on Thursday, October 24th. Morgan Stanley raised their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a report on Thursday, October 24th. Evercore ISI upped their price target on shares of Boston Scientific from $82.00 to $90.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Wells Fargo & Company lifted their target price on Boston Scientific from $87.00 to $98.00 and gave the stock an “overweight” rating in a report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $93.39.

Insider Transactions at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total value of $570,511.10. Following the sale, the executive vice president now directly owns 37,468 shares of the company’s stock, valued at approximately $3,061,135.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Boston Scientific news, CEO Michael F. Mahoney sold 162,777 shares of Boston Scientific stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the transaction, the chief executive officer now directly owns 1,572,096 shares in the company, valued at approximately $133,046,484.48. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total transaction of $570,511.10. Following the completion of the sale, the executive vice president now owns 37,468 shares of the company’s stock, valued at $3,061,135.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 309,270 shares of company stock valued at $26,196,718. Corporate insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.